Sakuraba H
Department of Clinical Genetics, Tokyo Metropolitan Institute of Medical Science.
Rinsho Byori. 1994 Jun;42(6):628-35.
Fabry disease is an X-linked inborn error of glycosphingolipid catabolism resulting from the deficient activity of the lysosomal hydrolase, alpha-galactosidase. Patients with classic Fabry disease of early onset show diverse clinical manifestations caused by generalized vasculopathy. Recent clinical and enzymatic examinations have revealed another form of this disease; progressive cardiomyopathy of late onset without other systemic signs or symptoms. Efforts were directed to identify the specific mutations in the alpha-galactosidase gene and to clarify the phenotype/genotype correlations. A variety of mutations, including deletions, nonsense mutations, splicing mutations and amino acid substitutions caused the classic form of Fabry manifestations, which resulted in the complete deficiency of alpha-galactosidase activity. Single base substitutions were detected in the upstream region of alpha-galactosidase gene exon 6, which resulted in residual enzyme activity. The degree of the expressed residual enzyme activity might determine the clinical phenotypes. Heterozygotes were successfully identified by gene analysis and immunofluorescence imaging diagnosis using confocal laser scanning microscopy.
法布里病是一种X连锁的鞘糖脂分解代谢先天性缺陷疾病,由溶酶体水解酶α-半乳糖苷酶活性缺乏所致。早发型经典法布里病患者表现出由全身性血管病变引起的多种临床表现。近期的临床和酶学检查发现了该病的另一种形式;迟发型进行性心肌病,无其他全身症状或体征。研究致力于确定α-半乳糖苷酶基因的特定突变,并阐明表型/基因型的相关性。包括缺失、无义突变、剪接突变和氨基酸取代在内的多种突变导致了经典型法布里病表现,致使α-半乳糖苷酶活性完全缺乏。在α-半乳糖苷酶基因外显子6的上游区域检测到单碱基取代,这导致了残余酶活性。所表达的残余酶活性程度可能决定临床表型。通过基因分析和使用共聚焦激光扫描显微镜的免疫荧光成像诊断成功鉴定出杂合子。